Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.
The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.
Bertolini
S
S
Department of Internal Medicine, University of Genoa, Italy.
Elicio
N
N
Daga
A
A
Degl'Innocenti
M L
ML
Balestreri
R
R
Fusi
M G
MG
Cotta Ramusino
A M
AM
Carozzi
A
A
D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D002214:Capsules; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011422:Propionates / Q000008:administration & dosage*
D000924:Anticholesteremic Agents; D002214:Capsules; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D011422:Propionates; C006012:fenofibric acid; D011345:Fenofibrate